EU closes Sanofi vaccine antitrust case without penalty
European Union antitrust regulators accepted Sanofi's proposed concessions to resolve an investigation into a campaign that allegedly misled people about a competing flu vaccine. Sanofi will not face a fine under the settlement.
EU competition enforcers have ended their antitrust probe into Sanofi after accepting the remedies the company offered. The investigation concerned allegations that Sanofi ran a campaign that gave misleading impressions about a rival influenza shot. Under the settlement, Sanofi avoids a financial penalty. The matter sits within broader scrutiny of how drugmakers promote their products against rivals, though the available details are limited.
The resolution may affect how vaccine makers communicate about competing products, potentially shaping the information patients and clinicians receive. It could also influence expectations for companies facing similar antitrust inquiries, suggesting that offering concessions might resolve cases without fines. For public health, the outcome may matter if it helps preserve fair competition and accurate vaccine information, though its practical effects remain uncertain.